References
- Björnsson E. (2009). Management of primary sclerosing cholangitis. Minerva Gastroenterol Dietol, 55, 163–72.
- Calich AL, Viana VS, Cancado E, et al. (2013). Anti-ribosomal P protein: A novel antibody in autoimmune hepatitis. Liver Int, 33, 909–13.
- Czaja AJ. (2005). Autoantibodies in autoimmune liver diseases. Adv Clin Chem, 40, 127–64.
- Czaja AJ. (2007). Autoimmune liver disease and rheumatic manifestations. Curr Opin Rheumatol, 19, 74–80.
- Decker P. (2006). Nucleosome autoantibodies. Clin Chim Acta, 366, 48–60.
- Fritzler MJ. (2008). Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun Rev, 7, 616–620.
- Fusconi M, Vannini A, Dall’aglio AC, et al. (2005). Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther, 22, 951–5.
- Klippel JH, Crofford L, Stone JH, Weyand CM. (2001). Primer on Rheumatic disease. Arthritis Foundation, 12th ed, Atlanta, p. 700.
- Koga T, Migita K, Miyashita T, et al. (2007). Determination of anticyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol, 25, 121–4.
- Koga T, Migita K, Miyashita T, et al. (2008). Determination of anti-cyclic citrulinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol, 26, 121–4.
- Krawitt EL. (2006). Autoimmune hepatitis. N Engl J Med, 354, 54–66.
- Lahita RG. (2004). Systemic Lupus erythematosus. 4th Ed. Elsevier. San Diego, California, p.1343.
- Lleo A, Invernizzi P, Mackay IR, et al. (2008). Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol, 14, 3328–37.
- Matsumoto T, Kobayashi S, Shimizu H, et al. (2000). The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver, 20, 366–73.
- Muratori P, Granito A, Pappas G, et al. (2009). The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol, 104(6), 1420–5
- Rust C, Beuers U. (2008). Overlap syndromes among autoimmune liver diseases. World J Gastroenterol, 14, 3368–73.
- Selmi C, Mackay IR, Gershwin ME. (2007). The immunological milieu of the liver. Semin Liver Dis, 27, 129–39.
- Sorrentino R. (2014). Genetics of autoimmunity: An update. Immunol Lett, 158, 116–9.
- Soultati AS, Dourakis SP. (2005). Hepatic manifestations of autoimmune rheumatic diseases. Ann Gastroenterol, 18, 309–24.
- Teufel A, Weinmann A, Kahaly GJ, et al. (2010). Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol, 44, 208–13.
- Tiegs G, Lohse AW. (2010). Immune tolerance: What is unique about the liver. J Autoimmun, 34, 1–6.
- Vannini A, Cheung K, Fusconi M, et al. (2007). Anti-CCP2 positivity in non-rheumatoid arthritis disease samples: Citrulline-dependent or not? Ann Rheum Dis, 66, 511–6.
- Yamagiwa S, Kamimura H, Takamura M, et al. (2014). Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol, 20, 2606–12.
- Youssef WI, Tavill AS. (2002). Connective tissue diseases and the liver. J Clin Gastroenterol, 35, 345–9.